Today: 28 February 2026
Subscribe
Browse Category

NYSE:LLY 28 January 2026 - 5 February 2026

Stock Market Today: S&P 500 futures steady after tech slump as Alphabet AI spending rattles investors

Stock Market Today: S&P 500 futures steady after tech slump as Alphabet AI spending rattles investors

Nasdaq 100 futures edged up 0.13% premarket Thursday after a sharp tech sell-off, while Dow futures slipped 0.20%. Alphabet shares tumbled over 6% after forecasting $175–$185 billion in 2026 capital spending for AI. The S&P 500 software and services index has lost 13% in a week, erasing $800 billion in value. The dollar hit a two-week high as risk aversion grew.
5 February 2026
···
Eli Lilly stock price jumps 10% after-hours on upbeat 2026 forecast and Q4 beat

Eli Lilly stock price jumps 10% after-hours on upbeat 2026 forecast and Q4 beat

Eli Lilly shares jumped 10.4% to $1,107.12 in after-hours trading Wednesday after reporting fourth-quarter revenue up 43% to $19.29 billion and a 2026 profit outlook above Wall Street forecasts. The company expects 2026 revenue of $80–83 billion and non-GAAP earnings per share of $33.50–$35.00. Mounjaro sales reached $7.41 billion and Zepbound $4.26 billion for the quarter.
4 February 2026
··
Eli Lilly stock jumps as 2026 forecast beats estimates on Zepbound, Mounjaro demand

Eli Lilly stock jumps as 2026 forecast beats estimates on Zepbound, Mounjaro demand

Eli Lilly shares surged about 9% Wednesday after reporting a 43% jump in quarterly revenue to $19.3 billion and issuing a bullish 2026 outlook. Mounjaro and Zepbound drove results, but executives warned pricing will weigh on future growth. Investors await the FDA’s April decision on Lilly’s oral obesity drug. The stock’s rally contrasted with declines in major indexes.
4 February 2026
···
Novo Nordisk stock plunges as 2026 sales warning fuels price-war fears around Wegovy

Novo Nordisk stock plunges as 2026 sales warning fuels price-war fears around Wegovy

Novo Nordisk shares fell 16% in Copenhagen after the company warned 2026 sales and profit may drop up to 13% due to falling U.S. drug prices and tougher competition. ADRs slid nearly 4% in New York. Novo plans a share buyback of up to 15 billion Danish crowns and named Jamey Millar as its new U.S. head. CEO Mike Doustdar said Wegovy price cuts have hit results but are meant to boost future demand.
4 February 2026
···
Dow Jones today: Dow edges higher as Lilly, Super Micro cushion Wall Street after AI software rout

Dow Jones today: Dow edges higher as Lilly, Super Micro cushion Wall Street after AI software rout

The Dow rose 0.4% at Wednesday’s open, led by gains in Eli Lilly and Super Micro Computer after strong earnings. The Nasdaq slipped 0.27% as investors remained wary of software stocks amid AI disruption fears. ADP reported U.S. private payrolls rose by just 22,000 in January, missing forecasts. President Trump signed a bill ending the partial government shutdown, but funding for Homeland Security runs out February 13.
4 February 2026
··
Eli Lilly stock in focus before earnings after Novo warns on obesity-drug price squeeze

Eli Lilly stock in focus before earnings after Novo warns on obesity-drug price squeeze

Eli Lilly shares fell 0.5% to $998.50 in premarket trading Wednesday after a 4% drop Tuesday, following Novo Nordisk’s warning of up to a 13% drop in 2026 sales and profits. Novo cut prices and launched an oral Wegovy, while Lilly plans to cap higher-dose obesity drug prices at $399 per month for repeat cash buyers. Investors await Lilly’s Q4 results and comments on pricing and competition.
4 February 2026
···
Eli Lilly stock price drops 4% as Novo outlook jars weight-loss trade ahead of earnings

Eli Lilly stock price drops 4% as Novo outlook jars weight-loss trade ahead of earnings

Eli Lilly shares fell 3.9% to $1,003.46 on Tuesday, tracking a sharp 14% drop in Novo Nordisk after its 2026 forecast signaled deeper pricing pressure in the obesity-drug market. Pfizer also slipped on new weight-loss drug data. Lilly will report quarterly results Wednesday, as investors watch for signs of further price cuts and shifting demand in the sector.
4 February 2026
····
Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings

Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings

Eli Lilly shares fell 1.4% to $1,029.99 by midday Tuesday as U.S. prices for GLP-1 obesity drugs dropped sharply, prompting analysts to cut long-term forecasts. Novo Nordisk and Pfizer reported strong weight-loss data for rival drugs this week, intensifying competition. Investors await Lilly’s earnings update Wednesday for signals on pricing, demand, and supply outlooks.
3 February 2026
·····
Eli Lilly stock price climbs as obesity-drug forecasts get a reality check before earnings

Eli Lilly stock price climbs as obesity-drug forecasts get a reality check before earnings

Eli Lilly shares rose 1.5% to close near $1,052.70 Monday, recovering from early losses ahead of its earnings report due Wednesday. Analysts have cut long-term forecasts for obesity drugs as prices fall and competition intensifies, with 2030 sales estimates for GLP-1 drugs dropping to about $100 billion. Investors are focused on Lilly’s pricing strategy and demand outlook. The FDA is set to rule on Lilly’s weight-loss pill by April 10.
2 February 2026
····
Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Eli Lilly shares rose 1.3% after announcing a $3.5 billion Pennsylvania plant for obesity drugs, helping the Health Care Select Sector SPDR Fund gain 0.6% as the S&P 500 fell. Biotech lagged, with Corcept Therapeutics dropping 10.6% after an FDA rejection. Thermo Fisher slid 2.3% on weak profit guidance. Stryker jumped 4.3% after raising its outlook.
31 January 2026
······
Eli Lilly stock price (LLY): $3.5B plant, EU Mounjaro call and earnings ahead — what to watch

Eli Lilly stock price (LLY): $3.5B plant, EU Mounjaro call and earnings ahead — what to watch

Eli Lilly shares rose 1.3% to $1,037.15 after announcing a $3.5 billion injectable drug plant in Pennsylvania, set to create 850 permanent jobs by 2031. The plant will produce next-generation weight-loss drugs, including retatrutide. The European regulator declined a new use for Mounjaro in heart failure but will update prescribing info. Lilly’s Q4 results are due Feb. 4.
31 January 2026
···
Eli Lilly stock climbs after $3.5 billion Pennsylvania plant plan as traders eye Feb. 4 results

Eli Lilly stock climbs after $3.5 billion Pennsylvania plant plan as traders eye Feb. 4 results

Eli Lilly shares rose 1.3% to $1,037.15 in after-hours trading Friday after announcing a $3.5 billion facility in Fogelsville, Pennsylvania to produce injectable weight-loss drugs, including retatrutide. Pennsylvania will contribute $100 million to the project, which is expected to create 850 permanent jobs and start operations by 2031.
31 January 2026
···
Eli Lilly stock barely budges after $1.93bn autoimmune pact; Trump touts six U.S. plants

Eli Lilly stock barely budges after $1.93bn autoimmune pact; Trump touts six U.S. plants

Eli Lilly shares closed up 0.03% at $1,024.14 after announcing new research deals in autoimmune disease and gene-editing for hearing loss. Repertoire Immune Medicines will receive $85 million upfront in a collaboration potentially worth $1.84 billion. Lilly also signed a gene-editing agreement with Seamless Therapeutics valued up to $1.12 billion. Investors await Feb. 4 earnings for updates on demand and supply.
30 January 2026
···
Eli Lilly stock price today: LLY rises on $1.93 billion Repertoire deal as earnings near

Eli Lilly stock price today: LLY rises on $1.93 billion Repertoire deal as earnings near

Eli Lilly shares rose 0.5% Thursday after Repertoire Immune Medicines announced a partnership with the company worth up to $1.93 billion. The deal follows Lilly’s $1.12 billion gene-editing agreement targeting hearing loss. Investors are also watching for Medicare’s plan to include Trulicity in upcoming price negotiations. Lilly’s earnings report is expected Feb. 4.
29 January 2026
····
Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer shares fell 1.8% to $26.02 after U.S. Medicare included Xeljanz in its upcoming drug price negotiations, set to begin in 2026 with prices effective in 2028. The Centers for Medicare & Medicaid Services named 15 drugs for talks, and companies must decide by February 28 whether to participate. Investors are awaiting Pfizer’s February 3 earnings for updates on pricing risks.
28 January 2026
······
Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal

Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal

Eli Lilly shares fell 2.4% to $1,015.05 Wednesday after the company announced a gene-editing deal with Seamless Therapeutics worth up to $1.12 billion. The U.S. government included Lilly’s Trulicity in the next round of Medicare drug-price negotiations, raising pricing concerns. Obesity drug rivals increased ad spending, intensifying competition.
28 January 2026
···
1 2 3 4 … 12
Go toTop